Franklin Resources, Inc. vs Biogen Inc — how do they compare? Franklin Resources, Inc. trades at $33.37 (market cap $16.95B), while Biogen Inc trades at $202.7 (market cap $30.13B). The key difference: Biogen Inc is the larger of the two by market cap, and Franklin Resources, Inc. pays a 3.96% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BEN | BIIB | |
|---|---|---|
Market Cap | $16.95B | $30.13B |
Sector | Financials | Health |
52-Week High | $35.77 | $216.63 |
52-Week Low | $21.18 | $128.93 |
Enterprise Value | $29.90B | $37.20B |
Dividend Yield | 3.96% | — |
Trailing returns across standard periods
Latest headlines on both assets
Franklin Resources provides investment services for individual and institutional investors. At the end of August 2022, Franklin had $1.388 trillion in managed assets, composed primarily of equity (32%), fixed-income (38%), multi-asset/balanced (10%) funds, alternatives (16%), and money market funds (4%). Distribution tends to be weighted more toward retail investors (49% of AUM) investors, as opposed to institutional (49%) and high-net-worth (2%) clients. Franklin is also one of the more global firms of the U.S.-based asset managers with more than 35% of its AUM invested in global/international strategies and 25% of managed assets sourced from clients domiciled outside the United States.
Read more on BEN →Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →